PMID- 36089694
OWN - NLM
STAT- Publisher
LR  - 20231019
IS  - 1538-9804 (Electronic)
IS  - 0162-220X (Linking)
VI  - 46
IP  - 6
DP  - 2023 Nov-Dec 01
TI  - Reaffirming Adverse Events Related to Lung Cancer Survivors' Target Therapies and 
      Their Apparent Effects on Fear of Cancer Progression, Anxiety, and Depression.
PG  - 488-495
LID - 10.1097/NCC.0000000000001147 [doi]
AB  - BACKGROUND: Most advanced non-small-cell lung cancer (NSCLC) patients received 
      targeted therapies of epidermal growth factor receptor tyrosine kinase 
      inhibitors. However, few studies reported the relationships between adverse 
      events (AEs) and psychological distress. OBJECTIVES: The aims of this study were 
      to (1) examine the differences in the incidence of AEs, fear of progression 
      (FoP), anxiety, and depression among 3 generations of epidermal growth factor 
      receptor tyrosine kinase inhibitors (first, gefitinib and erlotinib; second, 
      afatinib; third, osimertinib) and (2) examine the difference in levels of FoP, 
      anxiety, and depression between the presence and absence of AEs in NSCLC 
      patients. METHODS: This study used a cross-sectional study design. Patients with 
      NSCLC (N = 120) were recruited from a medical center in northern Taiwan. Adverse 
      events, FoP, anxiety, and depression were assessed by questionnaires. RESULTS: 
      The incidence rates of photosensitivity, mouth and throat sores, and diarrhea 
      were significantly high in the gefitinib, erlotinib, and afatinib groups, 
      respectively. A lesser proportion of patients experienced AEs in the osimertinib 
      group, compared with those in the gefitinib and erlotinib, and afatinib groups. 
      The incidence rates of FoP, anxiety, and depression were 13.8% to 26.0%, 24.1% to 
      40.4%, and 17.6% to 40.0%, respectively. Patients with photosensitivity, 
      paronychia, and alopecia had significantly higher levels of FoP, anxiety, and 
      depression. CONCLUSION: This study confirmed the priorities of care among 3 
      generations of epidermal growth factor receptor tyrosine kinase inhibitors in 
      NSCLC patients, using both the Common Terminology Criteria for Adverse Events 
      (CTCAE 4.03) and PRO-CTCAE 1.0. Photosensitivity, paronychia, and alopecia were 
      associated with higher levels of FoP, anxiety, and depression. Therefore, these 
      AEs require further management. IMPLICATIONS FOR PRACTICE: Our study suggests a 
      follow-up to address AEs and psychological distress.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Yu, Chu-Chun
AU  - Yu CC
AD  - Author Affiliations: Department of Nursing, National Taiwan University Hospital 
      (Mrs Yu, and Drs Lai and Lee); Department of Dermatology, National Taiwan 
      University Hospital, National Taiwan University College of Medicine (Dr Chu); 
      School of Nursing, College of Medicine, National Taiwan University (Drs Lai and 
      Lee); and Department of Nursing, National Taiwan University Cancer Center (Dr 
      Lai), Taipei; Department of Nursing, Mackay Medical College (Dr Hung and Ms 
      Chan), New Taipei City; Department of Nursing, Da-Yeh University (Dr Chen), 
      Changhua; and Department of Dermatology, Far Eastern Memorial Hospital (Dr Hsu), 
      New Taipei City, Taiwan.
FAU - Chu, Chia-Yu
AU  - Chu CY
FAU - Lai, Yeur-Hur
AU  - Lai YH
FAU - Hung, Chia-Tai
AU  - Hung CT
FAU - Chan, Jui-Chun
AU  - Chan JC
FAU - Chen, Yen-Ju
AU  - Chen YJ
FAU - Hsu, Hui-Te
AU  - Hsu HT
FAU - Lee, Yun-Hsiang
AU  - Lee YH
LA  - eng
PT  - Journal Article
DEP - 20221201
PL  - United States
TA  - Cancer Nurs
JT  - Cancer nursing
JID - 7805358
SB  - IM
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/13 06:00
CRDT- 2022/09/12 00:02
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/13 06:00 [medline]
PHST- 2022/09/12 00:02 [entrez]
AID - 00002820-990000000-00063 [pii]
AID - 10.1097/NCC.0000000000001147 [doi]
PST - ppublish
SO  - Cancer Nurs. 2023 Nov-Dec 01;46(6):488-495. doi: 10.1097/NCC.0000000000001147. 
      Epub 2022 Dec 1.